Shang Hai Zheng Quan Bao·2026-01-05 19:45Group 1: Fundraising Overview - The company raised a total of RMB 4,581,500,000 through its initial public offering, with a net amount of RMB 4,341,379,433.74 after deducting issuance costs [2] - The funds were deposited into a special account for management and were subject to a tripartite supervision agreement with the sponsor and the bank [2][3] Group 2: Fund Allocation and Project Adjustments - The company decided to terminate five research sub-projects and reallocate the unused funds to other ongoing and new sub-projects, including an investment of RMB 10 million to its wholly-owned subsidiary for a new flu vaccine project [3] - A special account was established for the "high-dose flu virus split vaccine" project, adhering to the principle of "special account storage and special fund usage" [4] Group 3: Tripartite Supervision Agreement - The tripartite agreement involves the company, its subsidiary, and the bank, ensuring that the funds are used exclusively for the designated project [5] - The agreement stipulates that any withdrawal exceeding 20% of the net fundraising amount must be reported to the sponsor within five working days [7] Group 4: Share Buyback Progress - The company plans to repurchase shares using between RMB 10 million and RMB 20 million of surplus funds, with a maximum price of RMB 38.00 per share [11] - As of December 31, 2025, the company had repurchased 384,899 shares, accounting for approximately 0.092% of the total share capital, with a total expenditure of RMB 10,789,216.56 [13]